Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
批准号:
9080961
负责人:
Giovanni Ferrari
金额:
$70.05万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2020-03-31
关键词:
AffectAgeAge-YearsAgreementAnimal ModelBioinformaticsBiological AssayBiomechanicsCanis familiarisCardiac Surgery proceduresCell ProliferationCellsClinicalDataDatabasesDiseaseDisease ProgressionDoseEventExcretory functionExtracellular MatrixFeasibility StudiesFrequenciesFunctional disorderGeneticGenetic PolymorphismGenotypeGrowthHeart ValvesHomeostasisHumanImageIn VitroInstitutional Review BoardsInterventionInvestigationLengthMaintenanceMediatingMitral ValveMitral Valve InsufficiencyMitral Valve ProlapseModelingMusNeurotransmittersOperative Surgical ProceduresOxidative StressPathogenesisPathway interactionsPatientsPhenotypePlayProcessProductionPromoter RegionsPtosisPublishingReactive Oxygen SpeciesReceptor SignalingRecurrenceRegistriesResearchRiskRoleSerotoninSignal TransductionSmall Interfering RNASpecimenTestingTherapeuticTissuesVariantWorkbaseconnective tissue growth factordecorindisorder controlhigh riskinterstitial celloperationpromoterpublic health relevancereceptorreceptor expressionreceptor-mediated signalingreconstructionrepairedresearch studyresponserestorationserotonin receptorserotonin transportertranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Myxomatous mitral valve (MV) disease (MMVD) affects over 140 million patients worldwide. This application is concerned with maintaining and restoring MV homeostasis in MMVD patients through investigations of serotonin (5HT) mechanisms that affect MMVD pathophysiology. 5HT is a neurotransmitter, which if present at increased levels can cause valvulopathies. Our research indicates that progression of MMVD is mediated by 5HT signaling via 5HT receptors (5HTR) 2A and 2B and by a specific 5HT transporter (SERT) polymorphism in the promoter region (LL-SERT, the full-length promoter) with a Mendelian distribution. Thus, MMVD appears to be a disorder with increased 5HTR responsiveness due to augmented levels of 5HTRs, and is exacerbated by maximal expression of SERT due to the LL-SERT genotype. Downstream processing post-SERT of 5HT results in increased reactive oxygen species (ROS) and TGF-β1 signaling. Specific Aim 1: To determine the impact of LL-SERT polymorphism in MMVD progression and recurrence after surgical repair and 5HT responsiveness. 1. a) Hypothesis: Patients with LL-SERT polymorphism are at higher risk of more rapid progression of MMVD, requiring surgery at a younger age; furthermore post-surgery this genotype with MMVD may have an increased risk for re-operation due to continuing 5HT-enhanced mechanisms. We will conduct genetic and bioinformatics analyses to determine occurrence, progression rate, and clinical recurrence of MVD patients based on SERT polymorphisms, SERT SNP variations, and imaging studies. 1. b) Hypothesis: VIC derived from patients with LL-SERT polymorphism are more responsive to 5HT stimulation resulting in MVICs activation and tissue remodeling. LL-, LS-, and SS-derived VICs and MV tissues will be isolated from MMVD patients and controls and exposed to 5HT stimulation. Endpoints will be MVICs phenotype, ROS production, and ECM remodeling. Specific Aim 2: To investigate the mechanisms of 5HTR signaling in human derived MV cells from all 3 SERT genotypes, focusing on TGF-β1 related pathways. 2. a) Hypothesis: Suppression of 5HTR2A & 2B expression in human derived MV cells and tissues controls cell phenotype and ECM. This subaim will use established siRNA constructs specific for 5HTR2A/2B to investigate their effects over a 5HT dose range, with endpoints including cell proliferation and ECM remodeling. This approach will also study SERT genotypes, SS, LL, and LS separately. 2. b) Hypothesis: Downstream TGF-β1 events related to 5HTR signaling mediate the progression of MMVD. These studies will investigate the effect of 5HTR-TGF-β1 interactions including studies of TGF- β1-receptor expression, TGF-β1 excretion, canonical and non-canonical signaling and the effects of TGF-β1 arising from 5HTR activity on ROS and ECM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of accelerated calcification and structural degeneration of implantable biomaterials in pediatric cardiac surgery
-
批准号:10655959
-
项目类别:
-
资助金额:$54.22万
-
财政年份:2023
-
负责人:Giovanni Ferrari
-
依托单位:
Oxidation-mediated structural degeneration of bioprosthetic heart valves
-
批准号:10202704
-
项目类别:
-
资助金额:$76.58万
-
财政年份:2018
-
负责人:Giovanni Ferrari
-
依托单位:
Role of Rage in Bicuspid Aortic Valve Symdrome
-
批准号:9762185
-
项目类别:
-
资助金额:$40.2万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Role of RAGE in Bicuspid Aortic Valve Syndrome
-
批准号:9313307
-
项目类别:
-
资助金额:$11.38万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
-
批准号:10361455
-
项目类别:
-
资助金额:$73.12万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Supplement to Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
-
批准号:10852158
-
项目类别:
-
资助金额:$59.5万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
-
批准号:10581593
-
项目类别:
-
资助金额:$72.18万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Role of Rage in Bicuspid Aortic Valve Symdrome
-
批准号:9677853
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Role of RAGE in Bicuspid Aortic Valve Syndrome
-
批准号:9175654
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and Restoration
-
批准号:9236213
-
项目类别:
-
资助金额:$66.45万
-
财政年份:2016
-
负责人:Giovanni Ferrari
-
依托单位:
Osteopontin: a Novel Biomarker for Calcific Aortic Valve Diseases
-
批准号:7934550
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Giovanni Ferrari
-
依托单位:
Osteopontin: a Novel Biomarker for Calcific Aortic Valve Diseases
-
批准号:7820910
-
项目类别:
-
资助金额:$49.92万
-
财政年份:2009
-
负责人:Giovanni Ferrari
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: